Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835497 · ClinicalTrials.gov registry record · Phase 1
5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00835497: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00835497 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00835497, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult subjects administered under fasting conditions.
Interventions
- DRUG 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
- DRUG 5 mg/500 mg METAGLIP™ Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835497
The ClinicalTrials.gov registry entry for NCT00835497 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets is the first listed.
NCT00835497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835497 about?
NCT00835497 is a clinical study titled "5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting". This study will compare the relative bioavailability (rate and extent of absorption) of 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets manufactured by TEVA Pharmaceutical Industries, Ltd., and distributed by TEVA Pharmaceuticals USA with that of 5 mg/500 mg METAGLIP™ Tablets by Bristol-Myers ...
What is the current status of trial NCT00835497?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-06. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00835497?
The interventions under investigation include: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets (DRUG), 5 mg/500 mg METAGLIP™ Tablets (DRUG).
Who is sponsoring clinical trial NCT00835497?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.